Literature DB >> 3934538

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

A Hamsten, B Wiman, U de Faire, M Blombäck.   

Abstract

Certain risk factors for myocardial infarction have been linked with disturbances in fibrinolytic activity. The recent development in our laboratory of new sensitive and specific methods for determination of tissue plasminogen activator (t-PA) activity and antigen, as well as the discovery of a new rapid inhibitor of this enzyme, enabled us to study fibrinolytic function in detail in a representative population of postinfarction patients. Seventy-one patients (62 men and 9 women) who had survived a myocardial infarction before the age of 45 were compared with 50 healthy subjects of similar age, three years after the infarction. Low t-PA activity after venous occlusion, mostly explained by high plasma levels of the t-PA inhibitor and to some extent by impaired release of t-PA from the vessel wall, was a frequent finding in the patients. The level of t-PA inhibitor was positively and significantly correlated with levels of serum triglycerides. Our data suggest that reduced fibrinolytic capacity due to increased plasma levels of a rapid inhibitor of t-PA may have pathogenetic importance in myocardial infarction, particularly in patients with hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934538     DOI: 10.1056/NEJM198512193132501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  141 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

Review 3.  Myocardial infarction in patients with normal coronary arteries: proposed pathogenesis and predisposing risk factors.

Authors:  S P Pinney; L E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

4.  The Jeremiah Metzger Lecture. Hypercoagulable states: challenges and opportunities.

Authors:  R L Nachman
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 5.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

6.  4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.

Authors:  Francesco Burzotta; Licia Iacoviello; Augusto Di Castelnuovo; Roberto Zamparelli; Andria D'Orazio; Concetta Amore; Rocco Schiavello; Maria Benedetta Donati; Attilio Maseri; GianFederico Possati; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 7.  Angiotensin and insulin resistance: conspiracy theory.

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Implications of plasma concentrations of adiponectin in patients with coronary artery disease.

Authors:  Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

9.  Angiotensinogen, angiotensine converting enzyme and plasminogen activator inhibitor-1 gene polymorphism in chronic allograft dysfunction.

Authors:  Negar Azarpira; M Bagheri; Gh A Raisjalali; M H Aghdaie; S Behzadi; H Salahi; M Rahsaz; M Darai; M J Ashraf; B Geramizadeh
Journal:  Mol Biol Rep       Date:  2008-05-03       Impact factor: 2.316

10.  Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis.

Authors:  Vincent M G Maher; Yuri Kitano; Clare Neuwirth; Graham J Davies; Attilio Maseri; Gilbert R Thompson; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2008-07-30       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.